Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy

Akira Arakawa,1,2 Maiko Inoue,2 Shimpei Sato,2 Shin Yamane,2 Kazuaki Kadonosono2 1Department of Ophthalmology, St Marianna University School of Medicine, Yokohama City Seibu Hospital, 2Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan Purpose: To evaluate the ef...

Full description

Bibliographic Details
Main Authors: Arakawa A, Inoue M, Sato S, Yamane S, Kadonosono K
Format: Article
Language:English
Published: Dove Medical Press 2017-04-01
Series:Clinical Ophthalmology
Subjects:
Online Access:https://www.dovepress.com/efficacy-of-intravitreal-aflibercept-injections-for-japanese-patients--peer-reviewed-article-OPTH
id doaj-6fc3226144924853a57d0c3aaef37725
record_format Article
spelling doaj-6fc3226144924853a57d0c3aaef377252020-11-24T22:52:48ZengDove Medical PressClinical Ophthalmology1177-54832017-04-01Volume 1179780232587Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathyArakawa AInoue MSato SYamane SKadonosono KAkira Arakawa,1,2 Maiko Inoue,2 Shimpei Sato,2 Shin Yamane,2 Kazuaki Kadonosono2 1Department of Ophthalmology, St Marianna University School of Medicine, Yokohama City Seibu Hospital, 2Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan Purpose: To evaluate the efficacy of intravitreal aflibercept therapy in treatment-naïve Japanese patients with polypoidal choroidal vasculopathy (PCV) using Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores.Subjects and methods: This study was a prospective, nonrandomized, interventional exploratory clinical trial performed in an institutional setting. Patients with PCV were treated with intravitreal aflibercept 2 mg/0.05 mL every 2 months after 3 initial monthly doses, for 1 year. Visual acuity test using the ETDRS chart and indocyanine green angiography was performed at baseline and at 6 and 12 months after initiating the treatment, in addition to routine examinations performed at each visit. The main outcome measure was the proportion of patients who achieved <15 ETDRS letter score loss.Results: Twenty-two patients were enrolled in this study. Nineteen (86%) patients were eligible for analysis. All the patients maintained their visual acuity (<15 ETDRS letter score loss) at 12 months. The ETDRS letter scores were 64.1 at baseline and 69.8 at 12 months (P<0.039). The polyps regressed completely in 14 (74%) patients at 12 months. Cataract progressed in 1 eye, but this progression was considered to be a senile change.Conclusions: Japanese patients with treatment-naïve PCV, who were treated with intravitreal aflibercept every 2 months after 3 initial monthly doses, exhibited a significant increase in ETDRS letter scores and a high rate of polyp resolution at 12 months. Keywords: aflibercept, polypoidal choroidal vasculopathy, Japanese, early treatment diabetic retinopathy study chart, polyp resolutionhttps://www.dovepress.com/efficacy-of-intravitreal-aflibercept-injections-for-japanese-patients--peer-reviewed-article-OPTHafliberceptpolypoidal choroidal vasculopathyJapaneseEarly Treatment Diabetic Retnipathy Study chart
collection DOAJ
language English
format Article
sources DOAJ
author Arakawa A
Inoue M
Sato S
Yamane S
Kadonosono K
spellingShingle Arakawa A
Inoue M
Sato S
Yamane S
Kadonosono K
Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy
Clinical Ophthalmology
aflibercept
polypoidal choroidal vasculopathy
Japanese
Early Treatment Diabetic Retnipathy Study chart
author_facet Arakawa A
Inoue M
Sato S
Yamane S
Kadonosono K
author_sort Arakawa A
title Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy
title_short Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy
title_full Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy
title_fullStr Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy
title_full_unstemmed Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy
title_sort efficacy of intravitreal aflibercept injections for japanese patients with polypoidal choroidal vasculopathy
publisher Dove Medical Press
series Clinical Ophthalmology
issn 1177-5483
publishDate 2017-04-01
description Akira Arakawa,1,2 Maiko Inoue,2 Shimpei Sato,2 Shin Yamane,2 Kazuaki Kadonosono2 1Department of Ophthalmology, St Marianna University School of Medicine, Yokohama City Seibu Hospital, 2Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan Purpose: To evaluate the efficacy of intravitreal aflibercept therapy in treatment-naïve Japanese patients with polypoidal choroidal vasculopathy (PCV) using Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores.Subjects and methods: This study was a prospective, nonrandomized, interventional exploratory clinical trial performed in an institutional setting. Patients with PCV were treated with intravitreal aflibercept 2 mg/0.05 mL every 2 months after 3 initial monthly doses, for 1 year. Visual acuity test using the ETDRS chart and indocyanine green angiography was performed at baseline and at 6 and 12 months after initiating the treatment, in addition to routine examinations performed at each visit. The main outcome measure was the proportion of patients who achieved <15 ETDRS letter score loss.Results: Twenty-two patients were enrolled in this study. Nineteen (86%) patients were eligible for analysis. All the patients maintained their visual acuity (<15 ETDRS letter score loss) at 12 months. The ETDRS letter scores were 64.1 at baseline and 69.8 at 12 months (P<0.039). The polyps regressed completely in 14 (74%) patients at 12 months. Cataract progressed in 1 eye, but this progression was considered to be a senile change.Conclusions: Japanese patients with treatment-naïve PCV, who were treated with intravitreal aflibercept every 2 months after 3 initial monthly doses, exhibited a significant increase in ETDRS letter scores and a high rate of polyp resolution at 12 months. Keywords: aflibercept, polypoidal choroidal vasculopathy, Japanese, early treatment diabetic retinopathy study chart, polyp resolution
topic aflibercept
polypoidal choroidal vasculopathy
Japanese
Early Treatment Diabetic Retnipathy Study chart
url https://www.dovepress.com/efficacy-of-intravitreal-aflibercept-injections-for-japanese-patients--peer-reviewed-article-OPTH
work_keys_str_mv AT arakawaa efficacyofintravitrealafliberceptinjectionsforjapanesepatientswithpolypoidalchoroidalvasculopathy
AT inouem efficacyofintravitrealafliberceptinjectionsforjapanesepatientswithpolypoidalchoroidalvasculopathy
AT satos efficacyofintravitrealafliberceptinjectionsforjapanesepatientswithpolypoidalchoroidalvasculopathy
AT yamanes efficacyofintravitrealafliberceptinjectionsforjapanesepatientswithpolypoidalchoroidalvasculopathy
AT kadonosonok efficacyofintravitrealafliberceptinjectionsforjapanesepatientswithpolypoidalchoroidalvasculopathy
_version_ 1725664551652818944